Investigation of therapeutic and protective effect of Reaferon-ES Lipint on mice infected with avian influenza virus (subtype H5N1)
Demina, O.K.; Sergeev, A.A.; Agafonov, A.P.; Shikov, A.N.; Sementsova, A.O.; Sergeev, A.A.; Sergeev, A.N.; Drozdov, I.G.
Antibiotiki i Khimioterapiia 54(9-10): 27-29
2009
ISSN/ISBN: 0235-2990 PMID: 20415260 Document Number: 630709
The efficacy of the therapeutic, prophylactic and urgent prophylactic schemes for the use of Reaferon-ES lipint, a liposomal human recombinant alpha-interferon for oral use, was studied on mice infected with the avian influenza virus. Strain A/Chicken/Kurgan /05/2005 (subtype H5N1) of the avian influenza virus showed high virulence with respect to mice ICR. Theoretically-based calculations allowed to design an optimal therapeutic and prophylactic dose of the drug for the mice (1000 units/animal). It was observed that only after prophylactic use of Reaferon-ES lipint it was effective in protection of the mice infected with 10 LD50 of the avian influenza virus (A/Chicken/Kurgan/05/2005, H5N1). The protection coefficient was 0.35. Under such conditions the drug efficacy was comparable with that of Tamiflu. Therefore, Reaferon-ES lipint could be recommended for prophylaxis of the infection due not only to the season strains of the influenza virus, but also to the strains of the avian influenza virus.